JP2015517493A5 - - Google Patents

Download PDF

Info

Publication number
JP2015517493A5
JP2015517493A5 JP2015511470A JP2015511470A JP2015517493A5 JP 2015517493 A5 JP2015517493 A5 JP 2015517493A5 JP 2015511470 A JP2015511470 A JP 2015511470A JP 2015511470 A JP2015511470 A JP 2015511470A JP 2015517493 A5 JP2015517493 A5 JP 2015517493A5
Authority
JP
Japan
Prior art keywords
bone
subject
cell
composition
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015511470A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015517493A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/032650 external-priority patent/WO2013169397A1/en
Publication of JP2015517493A publication Critical patent/JP2015517493A/ja
Publication of JP2015517493A5 publication Critical patent/JP2015517493A5/ja
Pending legal-status Critical Current

Links

JP2015511470A 2012-05-07 2013-03-15 新規オキシステロールアナログoxy149は、骨発生及びヘッジホッグシグナル伝達を誘導し、脂肪生成を阻害する Pending JP2015517493A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261643776P 2012-05-07 2012-05-07
US61/643,776 2012-05-07
PCT/US2013/032650 WO2013169397A1 (en) 2012-05-07 2013-03-15 Novel oxysterol analogue, oxy149, induces osteogenesis and hedgehog signaling and inhibits adipogenesis

Publications (2)

Publication Number Publication Date
JP2015517493A JP2015517493A (ja) 2015-06-22
JP2015517493A5 true JP2015517493A5 (https=) 2016-05-26

Family

ID=49551139

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015511470A Pending JP2015517493A (ja) 2012-05-07 2013-03-15 新規オキシステロールアナログoxy149は、骨発生及びヘッジホッグシグナル伝達を誘導し、脂肪生成を阻害する

Country Status (10)

Country Link
US (1) US20150140059A1 (https=)
EP (1) EP2847205A4 (https=)
JP (1) JP2015517493A (https=)
KR (1) KR20150008160A (https=)
CN (1) CN104507951B (https=)
AU (1) AU2013260057A1 (https=)
CA (1) CA2872734A1 (https=)
IN (1) IN2014DN09804A (https=)
RU (1) RU2014149153A (https=)
WO (1) WO2013169397A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9532994B2 (en) 2003-08-29 2017-01-03 The Regents Of The University Of California Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
US9670244B2 (en) 2006-02-27 2017-06-06 The Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
WO2009073186A1 (en) 2007-12-03 2009-06-11 The Regents Of The University Of California Oxsterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling
KR20150013232A (ko) 2012-05-07 2015-02-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 골형성 및 헤지호그 신호전달을 유도하고 지방생성을 억제하는 옥시스테롤 유사체 oxy133
CN105263500A (zh) * 2013-05-02 2016-01-20 加利福尼亚大学董事会 骨选择性成骨性氧固醇-骨靶向剂
GB201319776D0 (en) * 2013-11-08 2013-12-25 Allecra Therapeutics Sas Compound
CA2945404A1 (en) 2014-05-02 2015-11-05 The Regents Of The University Of California Bone-selective osteogenic oxysterol bisphosphonate analogs
US9657052B2 (en) 2014-12-09 2017-05-23 Warsaw Orthopedic, Inc. Compounds and methods of making sterols using diols
US10632230B2 (en) 2015-07-10 2020-04-28 Warsaw Orthopedic, Inc. Implants having a high drug load of an oxysterol and methods of use
US12171909B2 (en) 2015-07-10 2024-12-24 Warsaw Orthopedic, Inc. Implants having a drug load of an oxysterol and methods of use
US9637514B1 (en) 2015-10-26 2017-05-02 MAX BioPharma, Inc. Oxysterols and hedgehog signaling
US9987290B2 (en) 2016-03-28 2018-06-05 Warsaw Orthopedic, Inc. Methods for the separation and detection of an oxysterol
US20170275330A1 (en) * 2016-03-28 2017-09-28 Warsaw Orthopedic, Inc. Polymorphic forms of an oxysterol and methods of making them
US10688222B2 (en) 2016-11-21 2020-06-23 Warsaw Orthopedic, Inc. Lyophilized moldable implants containing an oxysterol
US11384114B2 (en) * 2016-12-09 2022-07-12 Warsaw Orthopedic, Inc. Polymorphic forms of an oxysterol and methods of making them
US10294264B2 (en) * 2017-04-21 2019-05-21 Warsaw Orthopedic, Inc. Oxysterol-therapeutic agent derivative for bone healing
US10434106B2 (en) 2017-05-19 2019-10-08 Warsaw Orthopedic, Inc. Oxysterol-statin compounds for bone growth
US11464888B2 (en) 2017-06-12 2022-10-11 Warsaw Orthopedic, Inc. Moldable formulations containing an oxysterol in an acellular tissue matrix
WO2019048898A1 (en) 2017-09-05 2019-03-14 INSERM (Institut National de la Santé et de la Recherche Médicale) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION
ES2972119T3 (es) 2018-08-10 2024-06-11 Alexion Pharma Inc Cicatrización ósea en implantes utilizando fosfatasa alcalina
US12083169B2 (en) 2021-02-12 2024-09-10 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06329697A (ja) * 1993-03-25 1994-11-29 Kowa Co 骨疾患治療剤
AU4682700A (en) * 1999-04-30 2000-11-17 Research Corporation Technologies, Inc. Bone targeting agents for osteoporosis
WO2005066114A1 (en) * 2003-12-24 2005-07-21 University Of Louisville Research Foundation Compounds for diagnosis, treatment and prevention of bone injury and metabolic disorders
US9670244B2 (en) * 2006-02-27 2017-06-06 The Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
EP2114415A4 (en) * 2007-02-23 2012-10-17 Univ Louisville Res Found METHOD AND COMPOUNDS FOR THE TARGETED RELEASE OF ACTIVE SUBSTANCES IN BONES FOR INTERACTION THEREOF
WO2008109780A1 (en) * 2007-03-06 2008-09-12 University Of Louisville Research Foundation, Inc Methods and compounds for the targeted delivery of agents to bone for interaction therewith
WO2009073186A1 (en) * 2007-12-03 2009-06-11 The Regents Of The University Of California Oxsterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling
WO2012024581A2 (en) * 2010-08-20 2012-02-23 Fate Therapeutics, Inc. Oxysterol compounds
WO2012024583A2 (en) * 2010-08-20 2012-02-23 Fate Therapeutics, Inc. Oxysterol compounds
WO2012024584A2 (en) * 2010-08-20 2012-02-23 Fate Therapeutics, Inc. Oxysterol compounds

Similar Documents

Publication Publication Date Title
JP2015517493A5 (https=)
JP2015518493A5 (https=)
RU2014149153A (ru) Новый аналог оксистерола, oxy149, индуцирует остеогенез и сигнальный путь hedgehog и ингибирует липогенез
Wang et al. The role of autophagy in bone metabolism and clinical significance
RU2014149164A (ru) Аналог оксистерола oxy133 индуцирует остеогенез и сигнальный путь hedgehog и ингибирует липогенез
Pilmane et al. Strontium and strontium ranelate: Historical review of some of their functions
Rutten et al. Low-intensity pulsed ultrasound increases bone volume, osteoid thickness and mineral apposition rate in the area of fracture healing in patients with a delayed union of the osteotomized fibula
Zhao et al. The promotion of bone healing by progranulin, a downstream molecule of BMP-2, through interacting with TNF/TNFR signaling
Shen et al. Pulsed electromagnetic fields stimulation affects BMD and local factor production of rats with disuse osteoporosis
JP2006503819A5 (https=)
Tao et al. Silibinin can promote bone regeneration of selenium hydrogel by reducing the oxidative stress pathway in ovariectomized rats
CA2643732A1 (en) Oxysterol compounds and the hedgehog pathway
KR20080114717A (ko) 골다공증의 치료를 위한 gsk-3 억제제
ES3041577T3 (en) Compositions comrising an opioid growth factor receptor (ogfr) antagonist for use in promoting bone formation and in the treatment of cancer.
Li et al. Selenium-modified calcium phosphate cement can accelerate bone regeneration of osteoporotic bone defect
Sheyn et al. PTH promotes allograft integration in a calvarial bone defect
Wang et al. Signalling pathways underlying pulsed electromagnetic fields in bone repair
Bradaschia-Correa et al. Ecto-5′-nucleotidase (CD73) regulates bone formation and remodeling during intramembranous bone repair in aging mice
Brüel et al. PTH (1–34), but not strontium ranelate counteract loss of trabecular thickness and bone strength in disuse osteopenic rats
Choi et al. Betulinic acid synergically enhances BMP2-induced bone formation via stimulating Smad 1/5/8 and p38 pathways
Sritharan et al. The synergistic effects of IL-6/IL-17A promote osteogenic differentiation by improving OPG/RANKL ratio and adhesion of MC3T3-E1 cells on hydroxyapatite
Singh et al. Biological basis of distraction osteogenesis–a review
Wang et al. Effects of pulsed electromagnetic field therapy at different frequencies on bone mass and microarchitecture in osteoporotic mice
ES2701675T3 (es) Irisina para el cuidado y la prevención de la osteoporosis
Rajfer et al. Prevention of osteoporosis in the ovariectomized rat by oral administration of a nutraceutical combination that stimulates nitric oxide production